A Real World Cost Comparison between Chinese Patients with Coronary Heart Disease or Angina Pectoris using Salvianolate and without using Salvianolate: A Retrospective Database Analysis

Abstract

Objective: To assess and compare 1-year cardiovascular events occurrence frequency and treatment cost among Chinese coronary heart disease (CHD) or angina pectoris patients who used salvianolate injection or non-user. Method: Data were obtained from electronic medical record (EMR) database between 2012.01.01~2017.12.31 covering medical encounter records from two tier-3 general hospitals from Shanghai and Guangzhou in China. Patients were followed 12 months after drug initiation. T-test, Chi-square test, negative binomial regression and generalized linear model adjusting for demographics, and baseline characteristics including cardiovascular event (myocardial infarction, angina, transient ischemic attack, stroke, etcs) rate, inpatient length of stay, and healthcare resource consumption were used to test the difference between two groups. Result: A total of 439 and 1848 patients were identified for salvianolate injection and control group, with mean (SD) age 75.42 (12.09) and 69.15 (12.79) (p<0.01) and male 43.28% and 52.38% (p<0.01), respectively. During baseline, the mean frequency of cardiovascular events were 2.05 and 5.82 times for treatment and control group respectively (p<0.01); the treatment cost for cardiovascular event were 4720.04 Chinese Yuan (CNY) and 3700.23 CNY for control group respectively (p=0.11). During the follow-up period, the average number of cardiovascular events were 0.26 and 5.87 times for treatment and control group respectively (p<0.01). Compared with non-user, mean per-year cost for salvianolate injection user was 29.58% lower (4069.21 vs. 5778.17 Chinese Yuan (CNY). Conclusion: Among Chinese coronary heart disease and angina pectoris patients, those who used salvianolate injection had lower per-year cardiovascular event rate and spent less on cardiovascular events treatment.